Evidence map›Paper›PMID 42660647›Full record

ArticleChemMedChem2026

(S)-Pyrrolo[1,2-a]pyrazine-3-carboxamide Analogs as Dual Akt/JNK Modulators With Antiproliferative Effects in MDA-MB-468 Cells.

Narges Hosseininasab, Sou Hyun Kim, Ye-Mi Kwon, Jungjin Park, Chanhyun Jung, Kwanghee Lee, Beom-Jun Wi, Su-Jin Yoo, Soonsil Hyun, Young-Suk Jung and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ChemMedChem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Narges HosseininasabCollege of Pharmacy, Chungbuk National University, Cheongju, Chungbuk, Republic of Korea.
Sou Hyun KimCollege of Pharmacy, Research Institute for Drug Development, Pusan National University, Busan, Republic of Korea.
Ye-Mi KwonDevelopment Center (NDDC), Daegu-Gyeongbuk Medical Innovation Foundation (KMEDIhub), Daegu, Republic of Korea.
Jungjin ParkCollege of Pharmacy, Chungbuk National University, Cheongju, Chungbuk, Republic of Korea.
Chanhyun JungCollege of Pharmacy, Chungbuk National University, Cheongju, Chungbuk, Republic of Korea.
Kwanghee LeeCollege of Pharmacy, Chungbuk National University, Cheongju, Chungbuk, Republic of Korea.
Beom-Jun WiCollege of Pharmacy, Chungbuk National University, Cheongju, Chungbuk, Republic of Korea.
Su-Jin YooCollege of Pharmacy, Chungbuk National University, Cheongju, Chungbuk, Republic of Korea.
Soonsil HyunCollege of Pharmacy, Chungbuk National University, Cheongju, Chungbuk, Republic of Korea.ORCID https://orcid.org/0000-0002-3400-7353
Young-Suk JungCollege of Pharmacy, Research Institute for Drug Development, Pusan National University, Busan, Republic of Korea.
Jae-Hwan KwakCollege of Pharmacy, Chungbuk National University, Cheongju, Chungbuk, Republic of Korea.ORCID https://orcid.org/0000-0003-2020-699X

Funding

Chungbuk National UniversityKorea government (MSIT)National Research Foundation of Korea RS-2023-NR076457
6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) remains a major clinical challenge due to the absence of effective targeted therapies. In this study, thirty analogs of (S)-1-oxo-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-3-carboxamide (A1-F5) were designed, synthesized, and evaluated for their cytotoxic activity against hormone receptor-positive breast cancer (MCF-7) and EGFR-overexpressing TNBC (MDA-MB-468) cell lines. Notably, compounds B1 and B3 exhibited potent growth inhibition toward MDA-MB-468 cells, with GI

Indexed as

Antineoplastic AgentsProtein Kinase InhibitorsProto-Oncogene Proteins c-aktPyrazinesPyrrolesApoptosisCell Line, TumorCell ProliferationDose-Response Relationship, DrugDrug Screening Assays, AntitumorHumansMolecular StructureStructure-Activity RelationshipAntineoplastic AgentsProtein Kinase InhibitorsProto-Oncogene Proteins c-aktPyrazinesPyrrolescytotoxic activityJNK phosphorylationMDA‐MB‐468 cellpyrrolopyrazine scaffoldtriple‐negative breast cancer

Identifiers

PMID42660647
PMCPMC13521716

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.